INDUCE-seq® On-Demand
Welcome to Ƶ
Ƶ is at the forefront of enhancing the safety and efficacy of gene editing therapies to enable transformative therapeutics to become a safe reality for patients.
About the technology
INDUCE-seq® is a game changing technology for the characterisation of genome breaks in cell & gene therapy applications.
Updates
-
Ƶ Renews Commitment to NIST Genome Editing Consortium, Bolstering Efforts to Standardize Gene Editing Safety
BOSTON & CAMBRIDGE, England–(BUSINESS WIRE)–Ƶ (“Broken String”), a leader in advancing gene editing safety, today announced its formal re-engagement as a member of the National Institute of Standards and Technology (NIST) Genome Editing Consortium. Broken String plays a key role in developing the gold-standard of safety testing for gene-editing therapies, based on its INDUCE-seq® platform….
-
Ƶ Featured in Genetic Engineering News
Quantifying the Breakome By Felix Dobbs, PhD August 1, 2025 Read on GEN Powered by gene editing advances like CRISPR and base editing, cell and gene therapy (CGT) is delivering on the promise of genomic medicine. First-generation CAR T-cell therapies, for example, have been functional cures for many patients with otherwise untreatable hematologic cancers. Newer gene…
-
Ƶ and BioLizard to Develop AI for Faster, Safer Gene Editing
Share BOSTON & CHICAGO & CAMBRIDGE, England–(BUSINESS WIRE)–Ƶ, a leader in advancing gene editing safety, and BioLizard, an expert in scientific data analytics and AI, today announced the development of SafeGuide, an AI tool for selecting safer, better guide RNAs (gRNA), the gene editing element that tells tools like CRISPR where to repair…
-
AI Meets Gene Editing: the Path to Plug-and-Play Drug Development
AI is no panacea, but it can have a role in turning artisanal, trial-and-error drug development into a rapid, cost-effective, data-driven process. By Felix Dobbs on July 10, 2025 8:58 am via MedCity News A generation ago, writing a piece like this about using artificial intelligence to develop genome-editing medicines would have sounded like a Star Trek plotline. But…
-
Steve Becker, Chief Commercial Officer, featured in article considering the key ethical and regulatory considerations in gene editing technologies.
Steve Becker, Chief Commercial Officer, Ƶ Gene editing therapies have already made a tremendous public impact, most recently with the N-of-1 CRISPR-edited gene therapy that was developed, cleared for clinical use by FDA, and treated a patient in under 8 months. The speed was impressive, but about half of that time was tied to…
-
Ƶ Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months
BOSTON, MA and Cambridge, UK, February 6, 2025 – Ƶ (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program…
-
Ƶ appoints Laurence Reid and Brad Crutchfield to its Board of Directors
Cambridge, UK, 23 September 2024: Ƶ (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors. Bringing extensive commercial and leadership expertise to the Board, Laurence…
-
Ƶ appoints Steve Becker as Chief Commercial Officer
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Ƶ (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…